Literature DB >> 11997017

Corticosteroid inhibits IL-4 signaling through down-regulation of IL-4 receptor and STAT6 activity.

Eui-Young So1, Seol-Hee Kim, Hyun-Hee Park, Byoung-Soo Cho, Choong-Eun Lee.   

Abstract

Corticosteroids are potent anti-inflammatory and immunosuppressive agents which down-regulate cytokine production and action. Yet, contradictory results have been reported for their effects on the interleukin (IL)-4-mediated response. Using type II Fc receptor for IgE/CD23 as a target gene, here we report that corticosteroids at 10(-4)-10(-6) M inhibit the IL-4 signaling pathway in human primary immune cells by down-regulation of the IL-4-induced IL-4 receptor expression and STAT6 activation. Although functional antagonism between steroid receptor and STAT6 for their transcriptional activity has been recently described, this is the first report that steroid inhibits the IL-4-induced STAT6 activity at the level of tyrosine phosphorylation and target DNA binding.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11997017     DOI: 10.1016/s0014-5793(02)02635-2

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  11 in total

1.  Altered phosphorylated signal transducer and activator of transcription profile of CD4+CD161+ T cells in asthma: modulation by allergic status and oral corticosteroids.

Authors:  Yael Gernez; Rabindra Tirouvanziam; Khoa D Nguyen; Leonard A Herzenberg; Alan M Krensky; Kari C Nadeau
Journal:  J Allergy Clin Immunol       Date:  2007-10-24       Impact factor: 10.793

2.  Cortisol promotes survival and regeneration of axotomised retinal ganglion cells and enhances effects of aurintricarboxylic acid.

Authors:  Peter Heiduschka; Solon Thanos
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-03-28       Impact factor: 3.117

Review 3.  Anti-CD23.

Authors:  Lanny J Rosenwasser; Jianfeng Meng
Journal:  Clin Rev Allergy Immunol       Date:  2005-08       Impact factor: 8.667

4.  Hodgkin lymphoma therapy with interleukin-4 receptor-directed cytotoxin in an infiltrating animal model.

Authors:  Mariko Kawakami; Koji Kawakami; Mitomu Kioi; Pamela Leland; Raj K Puri
Journal:  Blood       Date:  2004-12-30       Impact factor: 22.113

Review 5.  The changes in the T helper 1 (Th1) and T helper 2 (Th2) cytokine balance during HIV-1 infection are indicative of an allergic response to viral proteins that may be reversed by Th2 cytokine inhibitors and immune response modifiers--a review and hypothesis.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2004-01       Impact factor: 2.332

6.  Glucocorticoid inhibition of interleukin-4 (IL-4) and interleukin-13 (IL-13) induced up-regulation of arginase in rat airway fibroblasts.

Authors:  Dirk Lindemann; Kurt Racké
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-15       Impact factor: 3.000

7.  Baicalin relieves Mycoplasma pneumoniae infection‑induced lung injury through regulating microRNA‑221 to inhibit the TLR4/NF‑κB signaling pathway.

Authors:  Han Zhang; Xiang Li; Juan Wang; Qi Cheng; Yunxiao Shang; Guizhen Wang
Journal:  Mol Med Rep       Date:  2021-06-10       Impact factor: 2.952

Review 8.  Vaccinia virus pathogenicity in atopic dermatitis is caused by allergen-induced immune response that prevents the antiviral cellular and humoral immunity.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2003-12       Impact factor: 2.198

9.  Molecular blocking of CD23 supports its role in the pathogenesis of arthritis.

Authors:  Jérôme Rambert; Maria Mamani-Matsuda; Daniel Moynet; Pierre Dubus; Vanessa Desplat; Tina Kauss; Joël Dehais; Thierry Schaeverbeke; Khaled Ezzedine; Denis Malvy; Philippe Vincendeau; M Djavad Mossalayi
Journal:  PLoS One       Date:  2009-03-12       Impact factor: 3.240

10.  Interleukin-4 and 13 concentrations in infants at risk to develop Bronchopulmonary Dysplasia.

Authors:  R John Baier; John Loggins; Thomas E Kruger
Journal:  BMC Pediatr       Date:  2003-08-18       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.